Biocon Limited

Biocon Research Limited

Mylan Gmbh

Anuj Goel

Harish Iyer

Sanjay Tiwari

Mukesh Babuappa Patale

Chittnalli Ramegowda Naveen Kumar

Mayank Kumar Garg

Shrikumar Suryanarayan

Partha Hazra

Nitesh Dave

Ankur Bhatnagar

Saravanan Desan

Bimal Kumar

Sulekha Joshi

Saurabh Garg

Sneha Lakshmandas Hemdev

Nita Roy

Ruchika Srivastava

Goldy Sachdev

Deepthy Sathyanathan

Ramakrishnan Melarkode

Sambasivam Ganesh

Madhavan Sridharan

Anand Khedkar

Ramavana Gururaja

Acharya Poornaprajna

Madhav Kulkarni

Krishnamurthy Venkatesan

Gautam Krishnan

Vivekanandan Kannan

Govindasamy Manikam

H S Manjunath

Anupama Jagadish

Anoop Vasudevan

Lavanya Rao

Vana Raja

Mayank Garg

The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.

Methods for reducing accumulation of lactate during culturing and method for producing polypeptide

The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. In one embodiment antibody heterogeneity is reduced by the addition of divalent transitional metal ions such as zinc (Zn) to the cell culture medium. In another embodiment antibody heterogeneity is reduced by decreasing the osmolality of the cell culture medium.

Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof

The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogs, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as

Fermentation medias and processes thereof

The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as

The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms of insulin analogues such as glargine impurities characterized post expression in yeast based systems such as. The invention also relates to methods used to clone gene encoding the protein insulin glargine; inserting the related gene in a suitable yeast host; producing culture of the recombinant strain, stimulating expression of the heterologous polypeptide, its secretion and purification post fermentation and related enzymatic conversions.

Method of obtaining a purified, biologically active heterologous protein

The invention provides a process for the production of lipase inhibitors via an improvised fermentation process characterized in that a combinatorial feeding of linoleic acid or its esters or salts thereof and an omega-9 fatty acid, preferably oleic acid and/or its derivatives is employed during said process resulting in an improved yield co-efficient, productivity further providing ease of operation.

Fermentation process for higher yield coefficient of lipase-inhibitor with respect to consumed fatty acid

The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC&#x2014;CH&#x2014;CH&#x2014;(OCHCH)&#x2014;OCH.

Process for the preparation of insulin conjugate IN-105

In one aspect, the present invention provides an improved method for the manufacture of Pravastatin sodium salt by fermentation under optimal fermentation parameters using a new strain of

[object Object]

Growing community of inventors

Bengaluru, India

Anuj Goel